Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Pharmaceuticals Receives Orphan Drug Designation for Lower Volume, Shorter Infusion Time Bendamustine Hydrochloride Product for Chronic Lymphocytic Leukemia and Indolent B-Cell Non-Hodgkin’s Lymphoma 7/8/14 Eagle Pharmaceuticals Receives Tentative Approval for Patented, Ready-to-Dilute Bendamustine Hydrochloride Injection NDA 7/3/14 Eagle Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference 5/22/14 Eagle Pharmaceuticals, Inc. Reports Second Quarter 2014 Results 5/14/14 Eagle Pharmaceuticals Schedules Second Quarter Earning Release and Conference Call 5/1/14 Eagle Pharmaceuticals to Present at 39th Annual Deutsche Bank Health Care Conference 4/29/14 Eagle Pharmaceuticals’ Exclusive Licensor Granted U.S. Patent for Dantrolene in the Treatment of Heat Stroke 4/1/14 NDA for Eagle Pharmaceuticals’ Orphan Drug Ryanodex® for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted 3/20/14 Eagle Pharmaceuticals Announces Pricing of Initial Public Offering 2/11/14 Pagination First page Previous page Page 1 Current page 2
